ERYTHROMYCIN POLYLACTIC ACID MICROSPHERES FOR LUNG TARGETING

AIM: To prepare polylactic acid microspheres of Erythromycin for Lung targeting.METHEDS: The orthogonal test design was used to optimize the technology,of preparation. Thecharacter of the microspheres, drug release in vitro, stability and tissue distribution were examinedRESULTS: The Erythromycin polylactic acid microspheres was regular in its morphology. Drugwas enveloped in microspheres but not physically mixed with PDLLA. The average particle size was11.65μn with over 94% of the microspheres being in the range of 5～20trn; The drug loading andthe incorporation efciency were 18% and 60% respectively. The microspheres were stable for threemonth at 4 ℃ and room temperature. The in vitro release properties could be expressed by theHiguchi's equation: y = 28.067 + 3.8515t11/2 (r = 0.9834). Comparing with injection, the drug inmicrospheres was more concentrated in lung tissue. CONCLUSION: Erythromycin polylactic acidmicrospheres showed significant sustained release and lung targeting.

AIM: To prepare polylactic acid microspheres of Erythromycin for Lung targeting. METHEDS: The orthogonal test design was used to optimize the technology of preparation. The character of the microspheres, drug release in vitro, stability and tissue distribution were examined. RESULTS: The Erythromycin polylactic acid microspheres was regular in its morphology. Drug was enveloped in microspheres but not physically mixed with PDLLA. The average particle size was 11.65mm with over 94% of the microspheres being in the range of 5~20mm; The drug loading and the incorporation efficiency were 18% and 60% respectively. The microspheres were stable for three month at 4℃ and room temperature. The in vitro release properties could be expressed by the Higuchi抯 equation: y = 28.067 + 3.8515t1/2 (r = 0.9834). Comparing with injection, the drug in microspheres was more concentrated in lung tissue. CONCLUSION: Erythromycin polylactic acid microspheres showed significant sustained release and lung targeting.